Novartis P/E Ratio
Current P/E Ratio
37.47
High Valuation
Very High - High growth expectations or significantly overvalued
Novartis (NOVARTIND) P/E ratio is 37.47 (High), EPS (TTM) ₹37.74, current price ₹1487.70 on NSE — Very High - High growth expectations or significantly overvalued. Analyse NOVARTIND shareholding pattern to track promoter, FII and institutional holdings.
Current Valuation Metrics
P/E Ratio
37.47
Current Price
₹1487.70
EPS (TTM)
₹37.74
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
49.11
Sector Median
28.77
Sector Rank
#11 of 193
Sector Percentile
5.7%
NOVARTIND P/E Ratio — Valuation Signal & Historical Context
Novartis P/E 37.47 — signal: Overvalued. Browse NOVARTIND complete financial statements for revenue, profit, balance sheet and cash flow data.
- Stock appears overvalued with PE of 37.47, suggesting caution for new investments
- Trading at discount to sector average PE of 49.11
NOVARTIND vs Healthcare Peers — P/E Ratio Comparison
Novartis P/E 37.47 vs Healthcare average 49.11, median 28.77 — range 0.97–869.57.
Sector Average
49.11
Sector Median
28.77
Lowest P/E
0.97
Highest P/E
869.57
Companies
193
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 0.97 | ₹36 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.13 | ₹53 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.39 | ₹7,561 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.61 | ₹1,146 | Low |
| Amwill Health Care | AMWILL | 6.04 | ₹65 | Low |
| Mono Pharmacare | MONOPHARMA | 6.85 | ₹20 | Low |
| Medicamen Organics | MEDIORG | 6.94 | ₹28 | Low |
| Brooks Laboratories | BROOKS | 7.38 | ₹166 | Low |
| Shelter Pharma | SHELTER | 7.4 | ₹54 | Low |